David M. Pollock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David M. Pollock has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Jennifer S. Pollock
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia, 30912, United States
5 shared publications- John D. Imig
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, United States
5 shared publications Ahmed A. Elmarakby
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia, 30912, United States
3 shared publicationsJan Michael Williams
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA
3 shared publicationsTerry J. Opgenorth
Pharmaceutical Discovery Abbott Laboratories Abbott Park, Illinois
3 shared publications- Edward W. Inscho
Department of Physiology, Medical College of Georgia, Augusta, Georgia
2 shared publications
Latest Publications
- 1 September 2018
- Published by Wolters Kluwer Health in Hypertension
- Vol. 72 (Suppl_1)
Abstract 044: Purinoceptor-Dependent Regulation of Sodium Excretion is Sexually Dimorphic
Premenopausal women have a lower risk of hypertension compared to age-matched men. Recently, prominent roles have been assigned to P2Y 2 and P2Y 4 purinoceptor subtypes in promoting Na + excretion, implicating dysfunction of these receptors as potential contributors to hypertension. We recently reported that activation of P2Y 2 and P2Y 4 receptors in the renal medulla by UTP promotes Na + excretion in male rats. In intact females, UTP did not stimulate Na + excretion while ovariectomy unmasked UTP-induced natriuresis. These observations led us to hypothesize that intact females have higher basal renal medullary activity of P2Y 2 and P2Y 4 receptors in regulating Na + excretion compared to male and ovariectomized (OVX) rats. To test that, we determined (i) P2Y 2 and P2Y 4 mRNA and protein expression in the inner medulla from male, intact female and OVX Sprague Dawley rats and (ii) the effect of inhibiting medullary purinoceptors (P2 receptors) on Na + excretion in those rats. We found that P2Y 2 and P2Y 4 mRNA expression was higher in the inner medulla from females compared to males (1.00±0.09 vs. 0.70±0.05 and 1.00±0.22 vs. 0.29±0.05, respectively, P2 and P2Y 4 mRNA expression were eliminated by ovariectomy (0.60±0.06 and 0.29±0.04, respectively, p2 receptor, compared to males. In anesthetized rats, medullary P2 receptor inhibition by suramin (P2 receptor antagonist, 750 μg/kg/min) significantly attenuated Na + excretion in intact females (0.4±0.1 vs. 0.9±0.2 μmol/min, P2 ) increases the expression of P2Y 2 and P2Y 4 receptors, we subjected cultured mouse inner medullary collecting duct cells (mIMCD3) to different concentrations of E 2 (0, 10, 100 and 1000 nM). We found that E 2 dose-dependently increased the expression of P2Y 2 and P2Y 4 mRNA in mIMCD3. These data suggest that females have enhanced P2Y 2 and P2Y 4 -dependent regulation of Na + excretion in the renal medulla, compared to male and OVX rats, at least partially via an E 2 -dependent mechanism. This pathway may contribute to facilitated renal Na + handling in premenopausal females.
- 1 September 2018
- Published by Wolters Kluwer Health in Hypertension
- Vol. 72 (Suppl_1)
Abstract 044: Purinoceptor-Dependent Regulation of Sodium Excretion is Sexually Dimorphic
Premenopausal women have a lower risk of hypertension compared to age-matched men. Recently, prominent roles have been assigned to P2Y 2 and P2Y 4 purinoceptor subtypes in promoting Na + excretion, implicating dysfunction of these receptors as potential contributors to hypertension. We recently reported that activation of P2Y 2 and P2Y 4 receptors in the renal medulla by UTP promotes Na + excretion in male rats. In intact females, UTP did not stimulate Na + excretion while ovariectomy unmasked UTP-induced natriuresis. These observations led us to hypothesize that intact females have higher basal renal medullary activity of P2Y 2 and P2Y 4 receptors in regulating Na + excretion compared to male and ovariectomized (OVX) rats. To test that, we determined (i) P2Y 2 and P2Y 4 mRNA and protein expression in the inner medulla from male, intact female and OVX Sprague Dawley rats and (ii) the effect of inhibiting medullary purinoceptors (P2 receptors) on Na + excretion in those rats. We found that P2Y 2 and P2Y 4 mRNA expression was higher in the inner medulla from females compared to males (1.00±0.09 vs. 0.70±0.05 and 1.00±0.22 vs. 0.29±0.05, respectively, P2 and P2Y 4 mRNA expression were eliminated by ovariectomy (0.60±0.06 and 0.29±0.04, respectively, p2 receptor, compared to males. In anesthetized rats, medullary P2 receptor inhibition by suramin (P2 receptor antagonist, 750 μg/kg/min) significantly attenuated Na + excretion in intact females (0.4±0.1 vs. 0.9±0.2 μmol/min, P2 ) increases the expression of P2Y 2 and P2Y 4 receptors, we subjected cultured mouse inner medullary collecting duct cells (mIMCD3) to different concentrations of E 2 (0, 10, 100 and 1000 nM). We found that E 2 dose-dependently increased the expression of P2Y 2 and P2Y 4 mRNA in mIMCD3. These data suggest that females have enhanced P2Y 2 and P2Y 4 -dependent regulation of Na + excretion in the renal medulla, compared to male and OVX rats, at least partially via an E 2 -dependent mechanism. This pathway may contribute to facilitated renal Na + handling in premenopausal females.
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e16
High salt diet attenuates ET-1 mediated calcium signaling responses in preglomerular smooth muscle cells from WT and ETB receptor-deficient rats
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e16
Open AccessHigh salt diet attenuates ET-1 mediated calcium signaling responses in preglomerular smooth muscle cells from WT and ETB receptor-deficient rats
- 26 September 2006
- Published by Elsevier in Vascular Pharmacology
- Vol. 46 (2) , 144-151
Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension
- 26 September 2006
- Published by Elsevier in Vascular Pharmacology
- Vol. 46 (2) , 144-151
Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension
- 14 February 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (3) , 253-257
CONTRIBUTION OF PROSTANOID TP RECEPTORS TO THE PRESSOR AND INTRARENAL HAEMODYNAMIC RESPONSE TO ENDOTHELIN
SUMMARY: Previous studies have shown that endothelin (ET)‐1 stimulates thromboxane (Tx)A2production and so we hypothesized that inhibiting prostanoid TP receptors would prevent the pressor and intrarenal haemodynamic response to an acute infusion of ET‐1. Male Sprague‐Dawley rats were anaesthetized with Inactin (Sigma Chemical, St Louis, MO, USA; 50 mg/kg) and catheters were inserted into the femoral artery and vein for recording mean arterial pressure (MAP) and infusion of ET‐1 and receptor antagonists, respectively. A jugular vein catheter was used for the infusion of bovine serum albumin (6.2% in saline) during surgery (1.25% bodyweight). The pressor response to a 1 h infusion of ET‐1 (6 pmol/kg per min) was determined in rats that had been pretreated with vehicle (0.9% NaCl) or the TP receptor antagonist SQ29548 (2 mg/kg per h). Laser Doppler single‐optic fibres were implanted in the left kidney for the measurement of medullary blood flow (MBF) and cortical blood flow (CBF). Prostanoid TP receptor blockade completely inhibited the acute pressor response to ET‐1; the change in MAP was 14 2% versus ‐3 4% in vehicle and SQ29548 groups, respectively (P < 0.05). Endothelin‐1 reduced CBF (‐15.2 3.3%), a response that was not significantly changed by SQ29548 (‐6.2 7.6%). Similarly, the ET‐1‐mediated response in MBF was not altered by the TP receptor antagonist (7.7 4.9vs6.5 5.2%). To determine the influence of the ETBreceptor in modulating the response to ET‐1 during TP receptor blockade, additional groups were pretreated with A‐192621, an ETBreceptor‐selective antagonist (10 mg/kg, i.v.). A‐192621 potentiated the increase in MAP produced by ET‐1 (32 5%;P < 0.05vsET‐1 alone). SQ29548 significantly inhibited, but did not completely block, the increase in MAP produced by ET‐1 during ETBantagonist treatment (18 4%;P < 0.05). Endothelin‐1‐induced decreases in CBF were significantly enhanced in rats that were pretreated with A‐192621, whereas ET‐1 also significantly decreased MBF following A‐192621 treatment. During ETBreceptor blockade, TP receptor inhibition had no effect on the ET‐1‐mediated response of CBF and MBF. These results suggest that TP receptor activation is not involved in the renal haemodynamic responses to ET‐1. However, TP receptor activation contributes to the acute pressor response to ET‐1, but does not account for the potentiated increase in MAP during ETBreceptor blockade.
- 14 February 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (3) , 253-257
CONTRIBUTION OF PROSTANOID TP RECEPTORS TO THE PRESSOR AND INTRARENAL HAEMODYNAMIC RESPONSE TO ENDOTHELIN
SUMMARY: Previous studies have shown that endothelin (ET)‐1 stimulates thromboxane (Tx)A2production and so we hypothesized that inhibiting prostanoid TP receptors would prevent the pressor and intrarenal haemodynamic response to an acute infusion of ET‐1. Male Sprague‐Dawley rats were anaesthetized with Inactin (Sigma Chemical, St Louis, MO, USA; 50 mg/kg) and catheters were inserted into the femoral artery and vein for recording mean arterial pressure (MAP) and infusion of ET‐1 and receptor antagonists, respectively. A jugular vein catheter was used for the infusion of bovine serum albumin (6.2% in saline) during surgery (1.25% bodyweight). The pressor response to a 1 h infusion of ET‐1 (6 pmol/kg per min) was determined in rats that had been pretreated with vehicle (0.9% NaCl) or the TP receptor antagonist SQ29548 (2 mg/kg per h). Laser Doppler single‐optic fibres were implanted in the left kidney for the measurement of medullary blood flow (MBF) and cortical blood flow (CBF). Prostanoid TP receptor blockade completely inhibited the acute pressor response to ET‐1; the change in MAP was 14 2% versus ‐3 4% in vehicle and SQ29548 groups, respectively (P < 0.05). Endothelin‐1 reduced CBF (‐15.2 3.3%), a response that was not significantly changed by SQ29548 (‐6.2 7.6%). Similarly, the ET‐1‐mediated response in MBF was not altered by the TP receptor antagonist (7.7 4.9vs6.5 5.2%). To determine the influence of the ETBreceptor in modulating the response to ET‐1 during TP receptor blockade, additional groups were pretreated with A‐192621, an ETBreceptor‐selective antagonist (10 mg/kg, i.v.). A‐192621 potentiated the increase in MAP produced by ET‐1 (32 5%;P < 0.05vsET‐1 alone). SQ29548 significantly inhibited, but did not completely block, the increase in MAP produced by ET‐1 during ETBantagonist treatment (18 4%;P < 0.05). Endothelin‐1‐induced decreases in CBF were significantly enhanced in rats that were pretreated with A‐192621, whereas ET‐1 also significantly decreased MBF following A‐192621 treatment. During ETBreceptor blockade, TP receptor inhibition had no effect on the ET‐1‐mediated response of CBF and MBF. These results suggest that TP receptor activation is not involved in the renal haemodynamic responses to ET‐1. However, TP receptor activation contributes to the acute pressor response to ET‐1, but does not account for the potentiated increase in MAP during ETBreceptor blockade.
- 1 August 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 46 (2) , 366-371
Peroxisome Proliferator-Activated Receptor-α Activation Reduces Salt-Dependent Hypertension During Chronic Endothelin B Receptor Blockade
Endothelin B (ET B ) receptor stimulation inhibits sodium transport in a similar fashion as 20-HETE. Clofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, increases protein expression of cytochrome P450 4A (CYP4A), which is responsible for 20-HETE synthesis in the kidney. Experiments were designed to determine whether clofibrate reduces hypertension associated with chronic ET B receptor blockade. Male Sprague-Dawley rats received either normal-salt (0.8% NaCl) or high-salt (8% NaCl) diet for 10 days. Female rats were fed a high-salt (8% NaCl) diet for 10 days. During the last 7 days, rats of both sexes were divided into 3 treatment groups: (1) clofibrate in drinking water (80 mg per day), (2) ET B receptor antagonist A-192621 in food (10 mg/kg per day), or (3) clofibrate and A-192621. During ET B receptor blockade, clofibrate had no effect on mean arterial pressure (MAP) under normal salt conditions. In contrast, clofibrate significantly inhibited the increase in MAP produced by A-192621 in rats fed a high-salt diet (34±3 versus 19±4 mm Hg; P B receptor blockade significantly decreased CYP4A protein expression in the renal cortex of rats on high salt. Clofibrate significantly increased renal cortical and medullary CYP4A protein expression in A-192621–treated male rats on high salt. Therefore, chronic PPAR-α agonist treatment reduces salt-dependent hypertension produced by ET B receptor blockade in male and female Sprague-Dawley rats. This suggests a possible relationship between ET B receptor activation and the maintenance of CYP4A protein expression in the kidney of rats fed a high-salt diet.
- 1 August 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 46 (2) , 366-371
Peroxisome Proliferator-Activated Receptor-α Activation Reduces Salt-Dependent Hypertension During Chronic Endothelin B Receptor Blockade
Endothelin B (ET B ) receptor stimulation inhibits sodium transport in a similar fashion as 20-HETE. Clofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, increases protein expression of cytochrome P450 4A (CYP4A), which is responsible for 20-HETE synthesis in the kidney. Experiments were designed to determine whether clofibrate reduces hypertension associated with chronic ET B receptor blockade. Male Sprague-Dawley rats received either normal-salt (0.8% NaCl) or high-salt (8% NaCl) diet for 10 days. Female rats were fed a high-salt (8% NaCl) diet for 10 days. During the last 7 days, rats of both sexes were divided into 3 treatment groups: (1) clofibrate in drinking water (80 mg per day), (2) ET B receptor antagonist A-192621 in food (10 mg/kg per day), or (3) clofibrate and A-192621. During ET B receptor blockade, clofibrate had no effect on mean arterial pressure (MAP) under normal salt conditions. In contrast, clofibrate significantly inhibited the increase in MAP produced by A-192621 in rats fed a high-salt diet (34±3 versus 19±4 mm Hg; P B receptor blockade significantly decreased CYP4A protein expression in the renal cortex of rats on high salt. Clofibrate significantly increased renal cortical and medullary CYP4A protein expression in A-192621–treated male rats on high salt. Therefore, chronic PPAR-α agonist treatment reduces salt-dependent hypertension produced by ET B receptor blockade in male and female Sprague-Dawley rats. This suggests a possible relationship between ET B receptor activation and the maintenance of CYP4A protein expression in the kidney of rats fed a high-salt diet.
- Open Access
- 1 April 2005
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 288 (4) , F771-F777
L-type calcium channels in the renal microcirculatory response to endothelin
The signaling pathways of endothelin (ET)-1-mediated vasoconstriction in the renal circulation have not been elucidated but appear to be distinct between ETAand ETBreceptors. The purpose of this study was to determine the role of L-type Ca2+channels in the vasoconstrictor response to ET-1 and the ETBreceptor agonist sarafotoxin 6c (S6c) in the rat kidney. Renal blood flow (RBF) was measured with an ultrasonic flow probe in anesthetized rats, and a microcatheter was inserted into the renal artery for drug infusion. All rats were given vehicle (0.9% NaCl) or three successive bolus injections (1, 10, and 100 pmol) of ET-1 or S6c at 30-min intervals ( n = 6 in each group). ET-1 and S6c produced dose-dependent decreases in RBF. The Ca2+channel blocker nifedipine (1.5 μg) significantly attenuated the RBF response only at the highest doses of ET-1 and S6c. In the isolated blood-perfused juxtamedullary nephron preparation, Ca2+channel blockade with diltiazem had a very small inhibitory effect on ET-1-induced decreases in afferent arteriolar diameter only at the lowest concentrations of ET-1. In vascular smooth muscle cells isolated from preglomerular vessels, ET-1 produced a typical biphasic Ca2+response, whereas S6c had no effect on cytosolic Ca2+. Furthermore, Ca2+channel blockade (diltiazem or Ni2+) had no effect on the peak or sustained increase in cytosolic Ca2+produced by ET-1. These results support the hypothesis that L-type Ca2+channels play only a minor role in the constrictor responses to ET-1 in the renal microcirculation.
- 1 April 2005
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 288 (4) , F771-F777
Open AccessL-type calcium channels in the renal microcirculatory response to endothelin
The signaling pathways of endothelin (ET)-1-mediated vasoconstriction in the renal circulation have not been elucidated but appear to be distinct between ETAand ETBreceptors. The purpose of this study was to determine the role of L-type Ca2+channels in the vasoconstrictor response to ET-1 and the ETBreceptor agonist sarafotoxin 6c (S6c) in the rat kidney. Renal blood flow (RBF) was measured with an ultrasonic flow probe in anesthetized rats, and a microcatheter was inserted into the renal artery for drug infusion. All rats were given vehicle (0.9% NaCl) or three successive bolus injections (1, 10, and 100 pmol) of ET-1 or S6c at 30-min intervals ( n = 6 in each group). ET-1 and S6c produced dose-dependent decreases in RBF. The Ca2+channel blocker nifedipine (1.5 μg) significantly attenuated the RBF response only at the highest doses of ET-1 and S6c. In the isolated blood-perfused juxtamedullary nephron preparation, Ca2+channel blockade with diltiazem had a very small inhibitory effect on ET-1-induced decreases in afferent arteriolar diameter only at the lowest concentrations of ET-1. In vascular smooth muscle cells isolated from preglomerular vessels, ET-1 produced a typical biphasic Ca2+response, whereas S6c had no effect on cytosolic Ca2+. Furthermore, Ca2+channel blockade (diltiazem or Ni2+) had no effect on the peak or sustained increase in cytosolic Ca2+produced by ET-1. These results support the hypothesis that L-type Ca2+channels play only a minor role in the constrictor responses to ET-1 in the renal microcirculation.
- 1 February 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (2) , 283-287
NADPH Oxidase Inhibition Attenuates Oxidative Stress but Not Hypertension Produced by Chronic ET-1
Experiments were conducted to test the hypothesis that hypertension produced by chronic ET-1 infusion is mediated by NADPH oxidase-dependent superoxide production. Mean arterial pressure (MAP) was continuously monitored in male Sprague Dawley rats by telemetry. After baseline measurements, rats were placed on a high-salt diet (8% NaCl) and osmotic minipumps were implanted to infuse ET-1 (5 pmol/kg per minute intravenous) for 12 days. Control rats were maintained on the high-salt diet only. Separate groups of rats were also infused with ET-1 and given the superoxide dismutase mimetic, tempol (1 mmol/L), or the NADPH oxidase inhibitor, apocynin (1.5 mmol/L), in the drinking water. Infusion of ET-1 significantly increased MAP when compared with baseline values (132±3 versus 114±2 mm Hg, P P <0.05). Both tempol and apocynin treatment significantly attenuated the ET-1–induced increase in plasma 8-isoprostane (72±10 and 61±6 pg/mL, respectively). Similarly, ET-1 infusion also significantly increased aortic superoxide production (chemiluminescence and dihydroethidium staining techniques), which was prevented by both tempol and apocynin. These data provide evidence that chronic ET-1 infusion increases vascular NADPH oxidase-dependent superoxide production but does not account for chronic ET-1–induced hypertension.
- 1 February 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (2) , 283-287
NADPH Oxidase Inhibition Attenuates Oxidative Stress but Not Hypertension Produced by Chronic ET-1
Experiments were conducted to test the hypothesis that hypertension produced by chronic ET-1 infusion is mediated by NADPH oxidase-dependent superoxide production. Mean arterial pressure (MAP) was continuously monitored in male Sprague Dawley rats by telemetry. After baseline measurements, rats were placed on a high-salt diet (8% NaCl) and osmotic minipumps were implanted to infuse ET-1 (5 pmol/kg per minute intravenous) for 12 days. Control rats were maintained on the high-salt diet only. Separate groups of rats were also infused with ET-1 and given the superoxide dismutase mimetic, tempol (1 mmol/L), or the NADPH oxidase inhibitor, apocynin (1.5 mmol/L), in the drinking water. Infusion of ET-1 significantly increased MAP when compared with baseline values (132±3 versus 114±2 mm Hg, P P <0.05). Both tempol and apocynin treatment significantly attenuated the ET-1–induced increase in plasma 8-isoprostane (72±10 and 61±6 pg/mL, respectively). Similarly, ET-1 infusion also significantly increased aortic superoxide production (chemiluminescence and dihydroethidium staining techniques), which was prevented by both tempol and apocynin. These data provide evidence that chronic ET-1 infusion increases vascular NADPH oxidase-dependent superoxide production but does not account for chronic ET-1–induced hypertension.
- 1 May 2004
- Vol. 15 (5) , 1244-53
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Epoxyeicosatrienoic acids (EET) have antihypertensive and anti-inflammatory properties and play a role in the maintenance of renal vascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biologically active EET to dihydroxyeicosatrienoic acids (DHET). We hypothesized that soluble epoxide hydrolase (SEH) inhibition would improve renal vascular function and ameliorate hypertension induced renal damage. Chronic administration of the specific SEH inhibitor 1-cyclohexyl-3-dodecylurea (CDU, 3 mg/d) for 10 d lowered BP in angiotensin hypertensive rats. The contribution of renal vascular SEH to afferent arteriolar function in angiotensin hypertension was also assessed. SEH protein expression was increased in renal microvessels from hypertensive rats. Although CDU did not change afferent arteriolar responsiveness to angiotensin in normotensive animals, CDU treatment significantly attenuated afferent arteriolar diameter responses to angiotensin in hypertensive kidneys from 51% +/- 8% to 28% +/- 7%. Protection of the renal vasculature and glomerulus during chronic CDU administration was demonstrated by histology. Urinary albumin excretion, an index of renal damage, was also lower in CDU-treated hypertensive rats. These data demonstrate that SEH inhibition has antihypertensive and renal vascular protective effects in angiotensin hypertension and suggests that SEH inhibitors may be a useful therapeutic intervention for cardiovascular diseases.
- 1 May 2004
- Vol. 15 (5) , 1244-53
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Epoxyeicosatrienoic acids (EET) have antihypertensive and anti-inflammatory properties and play a role in the maintenance of renal vascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biologically active EET to dihydroxyeicosatrienoic acids (DHET). We hypothesized that soluble epoxide hydrolase (SEH) inhibition would improve renal vascular function and ameliorate hypertension induced renal damage. Chronic administration of the specific SEH inhibitor 1-cyclohexyl-3-dodecylurea (CDU, 3 mg/d) for 10 d lowered BP in angiotensin hypertensive rats. The contribution of renal vascular SEH to afferent arteriolar function in angiotensin hypertension was also assessed. SEH protein expression was increased in renal microvessels from hypertensive rats. Although CDU did not change afferent arteriolar responsiveness to angiotensin in normotensive animals, CDU treatment significantly attenuated afferent arteriolar diameter responses to angiotensin in hypertensive kidneys from 51% +/- 8% to 28% +/- 7%. Protection of the renal vasculature and glomerulus during chronic CDU administration was demonstrated by histology. Urinary albumin excretion, an index of renal damage, was also lower in CDU-treated hypertensive rats. These data demonstrate that SEH inhibition has antihypertensive and renal vascular protective effects in angiotensin hypertension and suggests that SEH inhibitors may be a useful therapeutic intervention for cardiovascular diseases.
- 1 December 2003
- Published by Elsevier in Vascular Pharmacology
- Vol. 40 (5) , 253-259
Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats
- 1 December 2003
- Published by Elsevier in Vascular Pharmacology
- Vol. 40 (5) , 253-259
Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats
- 1 October 2003
- Published by Wolters Kluwer Health in Hypertension
- Vol. 42 (4) , 775-780
Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases
The current study was designed to determine whether angiotensin II infusion could lead to persistent salt-sensitive hypertension and to examine involvement of renal microvascular epoxygenases in this process. Six groups were studied: rats maintained on a normal salt diet for 4 weeks (NS); rats maintained on a high salt diet for 4 weeks (HS); and all other animals receiving angiotensin II (ANG) infusion and being fed a normal or high salt diet for 2 weeks; then the angiotensin II infusion was stopped and diets were either maintained or switched (ANG/NS-NS, ANG/NS-HS, ANG/HS-HS, ANG/HS-NS). Angiotensin II infusion resulted in a rise in blood pressure and an increase in urinary albumin excretion over the 2-week period. After angiotensin II withdrawal, blood pressure returned to normal in animals receiving a normal salt diet from weeks 2 to 4 (ANG/NS-NS and ANG/HS-NS groups). In contrast, blood pressure remained elevated in the group maintained on a high salt diet throughout the entire 4-week period (ANG/HS-HS group). Renal microvascular CYP2C11 and CYP2C23 protein levels were decreased by 50% to 60% in the ANG/HS-HS group compared with the NS group. Likewise, renal microvascular CYP2J protein was significantly decreased in the ANG/HS-HS group versus the NS group. Renal microvascular CYP2C11 and CYP2C23 mRNA levels were reduced in the ANG/HS-HS group compared with both the NS and HS groups. These results support the hypothesis that angiotensin II infusion induces persistent salt-sensitive hypertension after withdrawal of angiotensin II that may be due to downregulation of CYP2C and CYP2J epoxygenases in renal microvessels.
- 1 October 2003
- Published by Wolters Kluwer Health in Hypertension
- Vol. 42 (4) , 775-780
Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases
The current study was designed to determine whether angiotensin II infusion could lead to persistent salt-sensitive hypertension and to examine involvement of renal microvascular epoxygenases in this process. Six groups were studied: rats maintained on a normal salt diet for 4 weeks (NS); rats maintained on a high salt diet for 4 weeks (HS); and all other animals receiving angiotensin II (ANG) infusion and being fed a normal or high salt diet for 2 weeks; then the angiotensin II infusion was stopped and diets were either maintained or switched (ANG/NS-NS, ANG/NS-HS, ANG/HS-HS, ANG/HS-NS). Angiotensin II infusion resulted in a rise in blood pressure and an increase in urinary albumin excretion over the 2-week period. After angiotensin II withdrawal, blood pressure returned to normal in animals receiving a normal salt diet from weeks 2 to 4 (ANG/NS-NS and ANG/HS-NS groups). In contrast, blood pressure remained elevated in the group maintained on a high salt diet throughout the entire 4-week period (ANG/HS-HS group). Renal microvascular CYP2C11 and CYP2C23 protein levels were decreased by 50% to 60% in the ANG/HS-HS group compared with the NS group. Likewise, renal microvascular CYP2J protein was significantly decreased in the ANG/HS-HS group versus the NS group. Renal microvascular CYP2C11 and CYP2C23 mRNA levels were reduced in the ANG/HS-HS group compared with both the NS and HS groups. These results support the hypothesis that angiotensin II infusion induces persistent salt-sensitive hypertension after withdrawal of angiotensin II that may be due to downregulation of CYP2C and CYP2J epoxygenases in renal microvessels.